Short Interest to Follow: Is Biolase Technology Incorporated (NASDAQ:BIOL) a Buy? The Stock Reported Less Sellers

November 25, 2016 - By Nellie Frank   ·   0 Comments

Short Interest to Follow: Is Biolase Technology Incorporated (NASDAQ:BIOL) a Buy? The Stock Reported Less Sellers

The stock of Biolase Technology Incorporated (NASDAQ:BIOL) registered a decrease of 1% in short interest. BIOL’s total short interest was 2.45 million shares in November as published by FINRA. Its down 1% from 2.48 million shares, reported previously. With 29,700 shares average volume, it will take short sellers 83 days to cover their BIOL’s short positions. The short interest to Biolase Technology Incorporated’s float is 8.17%. The stock increased 3.45% or $0.06 on November 25, hitting $1.8. About 23,526 shares traded hands. BIOLASE Inc (NASDAQ:BIOL) has risen 23.40% since April 22, 2016 and is uptrending. It has outperformed by 17.99% the S&P500.

BIOLASE, Inc. is a medical device firm that develops, makes, markets and sells laser systems in dentistry and medicine. The company has a market cap of $123.03 million. The Firm markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It currently has negative earnings. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems.

Insitutional Activity: The institutional sentiment decreased to 0.93 in Q2 2016. Its down 0.07, from 1 in 2016Q1. The ratio fall, as 6 funds sold all BIOLASE Inc shares owned while 7 reduced positions. 4 funds bought stakes while 9 increased positions. They now own 23.37 million shares or 0.00% more from 23.37 million shares in 2016Q1.
Gabelli Funds Limited Liability Corp accumulated 43,000 shares or 0% of the stock. Royal National Bank Of Canada holds 0% of its portfolio in BIOLASE Inc (NASDAQ:BIOL) for 2,194 shares. Blackrock Fund Advisors, a California-based fund reported 100,569 shares. Vanguard Gp has 0% invested in the company for 1.60 million shares. Guggenheim Limited Liability Corp holds 0% or 12,700 shares in its portfolio. Oracle Investment Incorporated has 2.87% invested in the company for 10.53M shares. Camber Cap Mngmt Ltd Liability Corp reported 5.33M shares or 0.3% of all its holdings. Birchview Cap L P accumulated 1.29 million shares or 1.09% of the stock. Wells Fargo & Com Mn has 243 shares for 0% of their US portfolio. Blackrock Advsrs Limited Liability Corporation, a Delaware-based fund reported 11,125 shares. Susquehanna Gp Llp owns 13,515 shares or 0% of their US portfolio. The New York-based Goldman Sachs Group has invested 0% in BIOLASE Inc (NASDAQ:BIOL). The Illinois-based Northern Tru Corporation has invested 0% in BIOLASE Inc (NASDAQ:BIOL). State Bank Of Mellon, a New York-based fund reported 42,222 shares. Barnett Incorporated has invested 0% of its portfolio in BIOLASE Inc (NASDAQ:BIOL).

BIOL Company Profile

BIOLASE, Inc. (BIOLASE), incorporated on February 10, 1987, is a medical device firm that develops, makes, markets and sells laser systems in dentistry and medicine. The Firm markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. The Company’s dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative and complex surgical applications. Combining its laser system products with imaging solutions provides dental professionals capabilities for early diagnosis and minimally invasive treatment. It markets and sells its laser systems in Canada, the European Union and other countries outside the United States.

More news for BIOLASE Inc (NASDAQ:BIOL) were recently published by: Prnewswire.com, which released: “SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BIOLASE, Inc …” on November 17, 2016. Streetinsider.com‘s article titled: “Form 8-K BIOLASE, INC For: Nov 22” and published on November 23, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Nellie Frank

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>